Viewing Study NCT00126009



Ignite Creation Date: 2024-05-05 @ 11:46 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00126009
Status: COMPLETED
Last Update Posted: 2008-04-10
First Post: 2005-07-18

Brief Title: SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients
Sponsor: Sanofi
Organization: Sanofi

Study Overview

Official Title: A 3-Month Open Randomised Trial Comparing the Efficacy and Safety of the Association Valproate-Amisulpride to the Association Valproate-Haloperidol in Bipolar I Patients Suffering From a Manic Episode
Status: COMPLETED
Status Verified Date: 2008-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective is

To compare the efficacy of the association valproate-amisulpride 400 to 800 mgday to the association valproate-haloperidol 5 to 15 mgday in bipolar I patients suffering from a manic episode according to DSM IV TR American Psychiatric Association APA 2000 and treated for a 3-month period

The secondary objectives are

To evaluate the clinical and biological safety of the association valproate-amisulpride to the association valproate-haloperidol
To assess the patient status 3 weeks and 3 months after inclusion and
To assess patient satisfaction at 3 months
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None